Zobrazeno 1 - 10
of 227
pro vyhledávání: '"Shorena, Janelidze"'
Autor:
Roman Sattarov, Megan Havers, Camilla Orbjörn, Erik Stomrud, Shorena Janelidze, Thomas Laurell, Niklas Mattsson-Carlgren
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-18 (2024)
Abstract Alzheimer’s disease (AD) is a debilitating neurodegenerative disorder characterized by brain aggregation of β-amyloid (Aβ) peptides and phosphorylated tau (P-tau) proteins. Extracellular vesicles (EVs) can be isolated and studied for pot
Externí odkaz:
https://doaj.org/article/59e547163a534427b4267f0eb07f69ea
Autor:
Anika Wuestefeld, Alexa Pichet Binette, Danielle van Westen, Olof Strandberg, Erik Stomrud, Niklas Mattsson-Carlgren, Shorena Janelidze, Ruben Smith, Sebastian Palmqvist, Hannah Baumeister, David Berron, Paul A. Yushkevich, Oskar Hansson, Nicola Spotorno, Laura E.M. Wisse
Publikováno v:
Alzheimer’s Research & Therapy, Vol 16, Iss 1, Pp 1-12 (2024)
Abstract Background The medial temporal lobe (MTL) is hypothesized to be relatively spared in early-onset Alzheimer’s disease (EOAD). Yet, detailed examination of MTL subfields and drivers of atrophy in amnestic EOAD is lacking. Methods BioFINDER-2
Externí odkaz:
https://doaj.org/article/b9abd4ab96174d0c88ed8964d092f79e
Autor:
Lyduine E. Collij, Sophie E. Mastenbroek, Niklas Mattsson-Carlgren, Olof Strandberg, Ruben Smith, Shorena Janelidze, Sebastian Palmqvist, Rik Ossenkoppele, Oskar Hansson
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-9 (2024)
Abstract Identifying concomitant Lewy body (LB) pathology through seed amplification assays (SAA) might enhance the diagnostic and prognostic work-up of Alzheimer’s disease (AD) in clinical practice and trials. This study examined whether LB pathol
Externí odkaz:
https://doaj.org/article/b424508f5d0d443ba15018c78ace4615
Autor:
Matthew D. Howe, Karysa J. Britton, Hannah E. Joyce, William Menard, Sheina Emrani, Zachary J. Kunicki, Melanie A. Faust, Brittany C. Dawson, Meghan C. Riddle, Edward D. Huey, Shorena Janelidze, Oskar Hansson, Stephen P. Salloway
Publikováno v:
Alzheimer’s Research & Therapy, Vol 16, Iss 1, Pp 1-14 (2024)
Abstract Background With the approval of disease-modifying treatments (DMTs) for early Alzheimer’s disease (AD), there is an increased need for efficient and non-invasive detection methods for cerebral amyloid-β (Aβ) pathology. Current methods, i
Externí odkaz:
https://doaj.org/article/45714cef87b14c3381fb405472bc50ab
Autor:
Anna Orduña Dolado, Erik Stomrud, Nicholas J. Ashton, Johanna Nilsson, Clara Quijano-Rubio, Alexander Jethwa, Wagner S. Brum, Ann Brinkmalm Westman, Henrik Zetterberg, Kaj Blennow, Shorena Janelidze, Oskar Hansson
Publikováno v:
Alzheimer’s Research & Therapy, Vol 16, Iss 1, Pp 1-10 (2024)
Abstract Background Studies suggest that cerebrospinal fluid (CSF) levels of amyloid-β (Aβ)42 and Aβ40 present a circadian rhythm. However sustained sampling of large volumes of CSF with indwelling intrathecal catheters used in most of these studi
Externí odkaz:
https://doaj.org/article/f78a34bbdde94bdab236ffea02e7059b
Autor:
Yoshiki Niimi, Shorena Janelidze, Kenichiro Sato, Naoki Tomita, Tadashi Tsukamoto, Takashi Kato, Kenji Yoshiyama, Hisatomo Kowa, Atsushi Iwata, Ryoko Ihara, Kazushi Suzuki, Kensaku Kasuga, Takeshi Ikeuchi, Kenji Ishii, Kengo Ito, Akinori Nakamura, Michio Senda, Theresa A. Day, Samantha C. Burnham, Leonardo Iaccarino, Michael J. Pontecorvo, Oskar Hansson, Takeshi Iwatsubo
Publikováno v:
Alzheimer’s Research & Therapy, Vol 16, Iss 1, Pp 1-12 (2024)
Abstract Background Maximizing the efficiency to screen amyloid-positive individuals in asymptomatic and non-demented aged population using blood-based biomarkers is essential for future success of clinical trials in the early stage of Alzheimer’s
Externí odkaz:
https://doaj.org/article/d12e8157ca6b40da9d6b4f81cfd4802f
Autor:
Linda Karlsson, Jacob Vogel, Ida Arvidsson, Kalle Åström, Shorena Janelidze, Kaj Blennow, Sebastian Palmqvist, Erik Stomrud, Niklas Mattsson-Carlgren, Oskar Hansson
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-15 (2024)
Abstract Cerebrospinal fluid (CSF) biomarkers reflect brain pathophysiology and are used extensively in translational research as well as in clinical practice for diagnosis of neurological diseases, e.g., Alzheimer’s disease (AD). However, CSF biom
Externí odkaz:
https://doaj.org/article/83a754f4856845649154ab6fc1777235
Autor:
Ida Arvidsson, Olof Strandberg, Sebastian Palmqvist, Erik Stomrud, Nicholas Cullen, Shorena Janelidze, Pontus Tideman, Anders Heyden, Karl Åström, Oskar Hansson, Niklas Mattsson-Carlgren
Publikováno v:
Alzheimer’s Research & Therapy, Vol 16, Iss 1, Pp 1-14 (2024)
Abstract Background Predicting future Alzheimer’s disease (AD)-related cognitive decline among individuals with subjective cognitive decline (SCD) or mild cognitive impairment (MCI) is an important task for healthcare. Structural brain imaging as m
Externí odkaz:
https://doaj.org/article/49a2d49cc014492c8756c4880a8e5d5c
Autor:
Wagner S. Brum, Nicholas C. Cullen, Joseph Therriault, Shorena Janelidze, Nesrine Rahmouni, Jenna Stevenson, Stijn Servaes, Andrea L. Benedet, Eduardo R. Zimmer, Erik Stomrud, Sebastian Palmqvist, Henrik Zetterberg, Giovanni B. Frisoni, Nicholas J. Ashton, Kaj Blennow, Niklas Mattsson-Carlgren, Pedro Rosa-Neto, Oskar Hansson
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-11 (2024)
Abstract Blood-based biomarkers for screening may guide tau positrion emissition tomography (PET) scan referrals to optimize prognostic evaluation in Alzheimer’s disease. Plasma Aβ42/Aβ40, pTau181, pTau217, pTau231, NfL, and GFAP were measured al
Externí odkaz:
https://doaj.org/article/45431c464f6049b581c84b0d07def687
Publikováno v:
Alzheimer’s Research & Therapy, Vol 16, Iss 1, Pp 1-10 (2024)
Abstract Introduction Pre-analytical factors can cause substantial variability in the measurements of cerebrospinal fluid (CSF) and plasma biomarkers of Alzheimer’s disease (AD). However, their effects on the performance of one of the most promisin
Externí odkaz:
https://doaj.org/article/36b149598f45468784621df045dd181c